Insecticides (India) Limited held its Board of Directors meeting on August 11, 2026, which commenced at 12:00 PM IST and concluded at 2:30 PM IST. The Board approved the Un-audited Standalone and Consolidated Financial Results for the quarter ended June 30, 2026, along with the Limited Review Report of the joint statutory auditors, M/s S S Kothari Mehta & Co., LLP and M/s Devesh Parekh & Co.

Standalone Financial Performance (Quarter Ended June 30, 2026)

  • Revenue from operations: ₹616.48 crore (compared to ₹691.37 crore in Q1 FY2026, down 10.8%)
  • Other income: ₹4.62 crore
  • Total income: ₹621.11 crore
  • Expenses breakdown:
  • Cost of materials consumed: ₹386.42 crore
  • Purchase of Stock-in-Trade: ₹76.71 crore
  • Changes in inventories: ₹(63.90) crore (negative indicates decrease)
  • Employee benefits expense: ₹44.98 crore
  • Finance costs: ₹4.65 crore
  • Depreciation and amortization: ₹9.59 crore
  • Other expenses: ₹76.39 crore
  • Total expenses: ₹564.84 crore
  • Profit before tax: ₹56.26 crore (compared to ₹76.85 crore in Q1 FY2026)
  • Tax expense: ₹14.43 crore (Current tax: ₹15.74 crore, Deferred tax: ₹(1.31) crore)
  • Profit for the period: ₹41.83 crore (compared to ₹57.30 crore in Q1 FY2026, down 27%)
  • Other comprehensive income (net of tax): ₹(1.59) crore
  • Total comprehensive income: ₹40.24 crore
  • Earnings per share (₹10 face value): Basic and Diluted EPS of ₹14.38
  • Paid-up equity share capital: ₹290.98 crore (unchanged)

Consolidated Financial Performance (Quarter Ended June 30, 2026)

  • Revenue from operations: ₹617.28 crore
  • Other income: ₹4.67 crore
  • Total income: ₹621.95 crore
  • Profit before tax and share of net profit: ₹58.82 crore
  • Share of net profit of jointly controlled entity: ₹0.27 crore
  • Profit before tax: ₹58.82 crore
  • Tax expense: ₹14.95 crore (Current tax: ₹16.52 crore, Deferred tax: ₹(1.57) crore)
  • Profit for the period: ₹43.87 crore
  • Total comprehensive income: ₹42.28 crore
  • Profit attributable to owners: ₹43.87 crore
  • Earnings per share (₹10 face value): Basic and Diluted EPS of ₹15.08

Key Notes and Disclosures

  • The financial results were prepared in accordance with Indian Accounting Standards (Ind AS) and SEBI Listing Regulations.
  • The company operates in one business segment: "Agro-Chemicals" comprising Technical & Formulation.
  • The dissolution of wholly owned subsidiary IIL Overseas DMCC, Dubai was approved by DMCCA on September 19, 2025.
  • The figures for the quarter ended March 31, 2026 are balancing figures between audited annual figures and previously published unaudited figures.
  • The consolidated results include subsidiaries IIL Biologicals Limited and Kaeros Research Limited, and jointly controlled entity OAT & IL India Laboratories Private Limited.
  • Subsidiaries contributed revenue of ₹57.09 crore and net profit of ₹2.89 crore for the quarter.
  • The jointly controlled entity contributed net profit of ₹0.27 crore and total comprehensive income of ₹0.26 crore.

Auditor Review

The joint statutory auditors conducted a limited review of both standalone and consolidated financial results and concluded that nothing has come to their attention that causes them to believe the statements contain any material misstatement.